Life Sciences Division, TRIUMF, Vancouver, Canada.
Department of Physics and Astronomy, University of British Columbia (UBC), Vancouver, Canada.
Phys Med Biol. 2022 Sep 12;67(18). doi: 10.1088/1361-6560/ac8b5f.
. The development of alpha-emitting radiopharmaceuticals usingAc ( = 9.92 d) benefits from the quantitative determination of its biodistribution and is not always easy to directly measure. An element-equivalent matched-pair would allow for more accurate biodistribution and dosimetry estimates.Ac ( = 29.4 h) is a candidate isotope forimaging of preclinicalAc radiopharmaceuticals, given its 158 keV and 230 keV gamma emissions making it suitable for quantitative SPECT imaging. This work aimed to conduct a performance assessment forAc imaging and presents the first-everAc SPECT images.. To establish imaging performance with regards to contrast and noise, image quality phantoms were scanned using a microSPECT/CT system. To assess the resolution, a hot rod phantom with cylindrical rods with diameters between 0.85 and 1.70 mm was additionally imaged. Two collimators were evaluated: a high-energy ultra-high resolution (HEUHR) collimator and an extra ultra-high sensitivity (UHS) collimator. Images were reconstructed from two distinct photopeaks at 158 keV and 230 keV.. The HEUHR SPECT image measurements of high activity concentration regions were consistent with values determined independently via gamma spectroscopy, within 9% error. The lower energy 158 keV photopeak images demonstrated slightly better contrast recovery. In the resolution phantom, the UHS collimator only resolved rods ≥1.30 mm and ≥1.50 mm for the 158 keV and 230 keV photopeaks, respectively, while the HEUHR collimator clearly resolved all rods, with resolution <0.85 mm.. Overall, the feasibility of preclinical imaging withAc was demonstrated with quantitative SPECT imaging achieved for both its 158 keV and 230 keV photopeaks. The HEUHR collimator is recommended for imagingAc activity distributions in small animals due to its resolution <0.85 mm. Future work will explore the feasibility of usingAc both as an element-equivalent isotope forAc radiopharmaceuticals, or as a standalone therapeutic isotope.
. 使用 Ac(=9.92d)发射的放射性药物的开发得益于其生物分布的定量测定,而直接测量并不总是容易的。元素等效配对可以更准确地估计生物分布和剂量。Ac(=29.4h)是一种用于临床前 Ac 放射性药物成像的候选同位素,因为其 158keV 和 230keV 伽马发射使其适合定量 SPECT 成像。这项工作旨在对 Ac 成像进行性能评估,并展示了有史以来的第一幅 Ac SPECT 图像。. 为了建立对比度和噪声方面的成像性能,使用 microSPECT/CT 系统对图像质量体模进行了扫描。为了评估分辨率,还对具有直径为 0.85 至 1.70mm 的圆柱形棒的热棒体模进行了成像。评估了两种准直器:高能超高分辨率(HEUHR)准直器和额外超高灵敏度(UHS)准直器。从两个不同的光峰(158keV 和 230keV)重建图像。. 在高活度浓度区域,HEUHR SPECT 图像测量值与通过伽马能谱独立确定的值一致,误差在 9%以内。低能 158keV 光峰图像显示出稍微更好的对比度恢复。在分辨率体模中,UHS 准直器仅在 158keV 和 230keV 光峰时分别分辨出直径≥1.30mm 和≥1.50mm 的棒,而 HEUHR 准直器则清楚地分辨出所有棒,分辨率<0.85mm。. 总之,通过对其 158keV 和 230keV 光峰进行定量 SPECT 成像,证明了使用 Ac 进行临床前成像的可行性。由于其分辨率<0.85mm,HEUHR 准直器推荐用于小动物的 Ac 活性分布成像。未来的工作将探索使用 Ac 作为 Ac 放射性药物的元素等效同位素或作为独立治疗同位素的可行性。